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ABSTRACT
The antiviral role of TRIM E3 ligases in vivo is not fully understood. To test the hypothesis that TRIM5 and TRIM22 have dif-
ferential transcriptional regulation and distinct anti-HIV roles according to infection phase and compartment, we measured
TRIM5, TRIM22, and type I interferon (IFN-I)-inducible myxovirus resistance protein A (MxA) levels in peripheral blood
mononuclear cells (PBMCs) during primary and chronic HIV-1 infection, with chronic infection samples being matched PBMCs
and central nervous system (CNS)-derived cells. Associations with biomarkers of disease progression were explored. The impact
of IFN-I, select proinflammatory cytokines, and HIV on TRIM E3 ligase-specific expression was investigated. PBMCs from indi-
viduals with primary and chronic HIV-1 infection had significantly higher levels of MxA and TRIM22 than did PBMCs from
HIV-1-negative individuals (P < 0.05 for all comparisons). PBMCs from chronic infection had lower levels of TRIM5 than did
PBMCs from primary infection or HIV-1-uninfected PBMCs (P  0.0001 for both). In matched CNS-derived samples and PB-
MCs, higher levels of MxA (P  0.001) and TRIM5 (P  0.0001) in the CNS were noted. There was a negative correlation be-
tween TRIM22 levels in PBMCs and plasma viral load (r  0.40; P  0.04). In vitro, IFN-I and, rarely, proinflammatory cyto-
kines induced TRIM5 and TRIM22 in a cell type-dependent manner, and the knockdown of either protein in CD4
lymphocytes resulted in increased HIV-1 infection. These data suggest that there are infection-phase-specific and anatomically
compartmentalized differences in TRIM5 and TRIM22 regulation involving primarily IFN-I and specific cell types and indicate
subtle differences in the antiviral roles and transcriptional regulation of TRIM E3 ligases in vivo.
IMPORTANCE
Type I interferon-inducible TRIM E3 ligases are a family of intracellular proteins with potent antiviral activities mediated
through diverse mechanisms. However, little is known about the contribution of these proteins to antiviral immunity in vivo
and how their expression is regulated. We show here that TRIM5 and TRIM22, two prominent members of the family, have
different expression patterns in vivo and that the expression pattern depends on HIV-1 infection status and phase. Furthermore,
expression differs in peripheral blood versus central nervous system anatomical sites of infection. Only TRIM22 expression cor-
related negatively with HIV-1 viral load, but gene silencing of both proteins enhances HIV-1 infection of target cells. We report
subtle differences in TRIM5 and TRIM22 gene induction by IFN-I and proinflammatory cytokines in CD4 lymphocytes,
monocytes, and neuronal cells. This study enhances our understanding of antiviral immunity by intrinsic antiviral factors and
how their expression is determined.
Induction of the type I interferons (IFNs) IFN- and IFN- is ahallmark of and one of the earliest immune responses of mam-
malian cells to viral infection (1). The role of IFN-/ in HIV-1
infection is controversial, as some studies have shown protective
roles of IFN-I (2, 3), while others have highlighted the pathologi-
cal roles of IFN-I (2). Nevertheless, administration of recombi-
nant human IFN- to patients in the asymptomatic phase of
HIV-1 infection is beneficial, with attenuated CD4 T cell decline
and reductions in the incidence of AIDS-defining events, although
these effects were not observed in more advanced disease (4, 5).
Transiently high levels of endogenous serum IFN- have been
described for primary HIV-1 infection (6, 7).
Type I interferons induce the expression of some members of
the antiviral tripartite motif (TRIM) E3 ligase family, which con-
sists of approximately 100 distinct proteins characterized by the
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presence of a RING domain, one or two B boxes, and a coiled-coil
domain (8–11). TRIM5, the best characterized of these proteins,
blocks HIV-1 replication in Old World monkey cells through a
direct interaction with the viral capsid (12, 13). TRIM5 is re-
sponsible for species-specific postentry restriction of retroviruses
such as murine leukemia N-tropic virus (N-MLV) and HIV-1 in
primate cells (13, 14). TRIM22 is also induced by IFN-I and in-
hibits viral replication by interfering with viral gene transcription
and virion assembly (15–19). Genetic association studies have
demonstrated that polymorphic variants of the human TRIM5
gene are associated with reduced susceptibility to HIV infection or
are overrepresented among HIV-negative individuals compared
to HIV-positive ones (20, 21), suggesting that human TRIM5
may have some protective role against HIV-1 infection. It has also
been reported that human TRIM5 genetic variants can influence
the rate of disease progression, although the effects appear to be
dependent on the phase of infection and of modest magnitude
(22, 23). Human TRIM5 may also select for escape mutants after
a prolonged duration of HIV-1 infection (24), suggesting ongoing
immune pressure during infection. In a prospective cohort study
of HIV-1-negative individuals at high risk for HIV-1 infection, we
showed that elevated expression levels of TRIM5 were associated
with decreased susceptibility to HIV-1 infection (25). We subse-
quently found that TRIM22 but not TRIM5, IFN-, IFN-, or
myxovirus resistance protein A (MxA) expression correlated neg-
atively with plasma viral load and positively with CD4 T cell
counts in primary HIV-1 infection, suggesting a protective, anti-
viral role in vivo (17).
The role of TRIM E3 ligases as an important component of
innate defense against HIV-1 is therefore now well established.
However, little is known about whether TRIM E3 ligases have
significant antiviral activity in vivo or how they may be regulated
and affected by HIV-1 infection. We hypothesized that TRIM E3
ligases contribute significantly to anti-HIV-1 immunity during
the early phases of infection, as has been demonstrated with other
components of antiviral innate immune mechanisms. Alterna-
tively, the antiviral impact of these factors may become more pro-
nounced as adaptive immune mechanisms become progressively
dysfunctional in chronic HIV-1 infection. Furthermore, we rea-
soned that innate defenses such as TRIM E3 ligases may be more
important in remote or immune-privileged sites without well-
developed adaptive immune systems. We therefore studied the
relationship between the expression of IFN-I and TRIM5 and
TRIM22 in primary and chronic HIV-1 infection and in periph-
eral blood- and central nervous system (CNS)-derived cells. We
explored the in vivo association between TRIM E3 ligase expres-
sion levels and biomarkers of HIV-1 disease progression. Finally,
we explored in vitro the role of select proinflammatory cytokines
in the regulation of TRIM E3 ligases and the impact of gene silenc-
ing of these antiviral factors on HIV-1 replication in CD4 T cells.
MATERIALS AND METHODS
Subjects. Study subjects were part of the CAPRISA 002 acute infection
study, which is an observational natural history study of HIV-1 subtype C
infection established in Durban, South Africa, in 2004 (25, 26). Briefly, the
cohort consisted of 245 high-risk seronegative women who were followed
up to identify acute or recent infections. Participants were enrolled into
the primary infection phase if they were antibody positive within 5
months of a previous antibody-negative test or if they had evidence of
virus replication without HIV-1 antibodies, as assessed by rapid tests and
PCR testing. Women from other seroincident cohorts in Durban were
enrolled into the CAPRISA 002 study if they met the above-described
criteria. Time of infection was defined as the midpoint between the last
HIV-1 antibody-negative test and the first HIV-1 antibody-positive test or
14 days prior to the first positive HIV-1 RNA PCR assay for those indi-
viduals identified as being antibody negative but HIV-1 RNA PCR posi-
tive. Peripheral blood mononuclear cells (PBMCs) from a total of 19
HIV-1-uninfected and 28 recently infected individuals from the
CAPRISA study cohort were available for use in this study. We analyzed
samples at a single time point within 12 months postinfection and defined
this as primary infection.
We also analyzed matched PBMC and cerebrospinal fluid (CSF) sam-
ples from a separate cohort of individuals presenting with chronic men-
ingitis, as described previously (27). Briefly, 150 consecutive patients with
suspected tuberculous meningitis (TBM) were prospectively recruited be-
tween January 2008 and April 2009 at the Inkosi Albert Luthuli Central
Hospital (IALCH) in Durban, South Africa. All patients were clinically
assessed by a neurologist and had a computerized tomography (CT) scan
done to exclude contraindications for a lumbar puncture (LP). A total of
26 HIV-1-positive samples were analyzed. All patients analyzed were an-
tiretroviral naive. The study was approved by the Biomedical Research
Ethics Committee of the University of KwaZulu-Natal, and participants
provided written informed consent.
Sample processing, viral load quantification, and CD4 cell enumer-
ation. PBMCs were isolated by Ficoll-Histopaque (Sigma, St. Louis, MO)
density gradient centrifugation from blood within 6 h of blood collection
and frozen in liquid nitrogen until use. Six milliliters of whole CSF was
spun at 1,800 rpm in an Eppendorf centrifuge (catalog no. 5430) for 10
min, and cell pellets were washed and resuspended in 1 ml RPMI 1640
(supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml
streptomycin, and 10% fetal calf serum). Cells were immediately counted
and lysed for RNA extractions. Viral load was determined by using the
automated Cobas Amplicor HIV-1 Monitor Test v1.5 (Roche Molecular
Systems, Inc., Branchburg, NJ) on plasma and CSF samples. CD4 cells
were enumerated by using the Multitest kit (CD4/CD3/CD8/CD45) on a
four-parameter FACSCalibur flow cytometer (Becton, Dickinson, Frank-
lin Lakes, NJ).
Cell sorting. We employed magnetically activated cell sorting MACS
(Miltenyi Biotec, Bergisch Gladbach, Germany, and Stemcell Technolo-
gies, Vancouver, Canada) to isolate the different cell populations from six
fresh HIV-1-negative PBMC samples. Purity was assessed by fluores-
cence-activated cell sorter (FACS) analysis. CD4 cells were isolated by
using negative-selection CD4 T Cell Isolation kit II MACS (Miltenyi
Biotec, Bergisch Gladbach, Germany), and monocytes were isolated by
using negative-selection Monocytes Isolation kit II MACS (Miltenyi Bio-
tec, Bergisch Gladbach, Germany). Natural killer (NK) cells were isolated
by using the Easy Sep negative-selection human NK cell enrichment kit
(Stemcell Technologies, Vancouver, Canada). The purity achieved ranged
between 85% and 95%.
FACS analysis. Nine matched PBMC or CSF pellets were surface
stained on ice with the following murine anti-human monoclonal anti-
bodies: anti-CD3-fluorescein isothiocyanate (FITC), anti-CD4-peridinin
chlorophyll protein (PerCP), and anti-CD8-PerCP markers for T cells;
anti-CD19-phycoerythrin (PE) for B cells; anti-CD14-allophycocyanin
(APC) for monocytes; and anti-CD56-PE-Cy7 and anti-CD16-PE for NK
cells (Becton, Dickinson). Stained cells were washed in phosphate-buff-
ered saline (PBS) and fixed with 1% formaldehyde. Between 50,000 and
100,000 events were acquired per sample on an LSRII flow cytometer, and
data analysis was performed by using FlowJo version 8.8.2 (TreeStar, Inc.,
Ashland, OR).
Cell lines and reagents. Human astroglioma cells (U87.CD4.CCR5)
(catalog no. 4035; NIH AIDS Reagent Repository) and neuroblastoma
cells (ATCC CRL-2137; ATCC, Rockville, MD) were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) with 2 mM L-glutamine, 100
U/ml penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum
(FBS). Recombinant human alpha 2b interferon (IFN-2b) (catalog no.
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CYT-205), interleukin-2 (IL-2) (catalog no. CYT-209), and tumor necro-
sis factor alpha (TNF-) (catalog no. CYT-223) were purchased from
Prospec (East Brunswick, NJ).
IFN- and cytokine stimulation of cells. CD4 cells, monocytes, as-
trocytes, and neuroblasts in 24-well plates (1  106 cells/well) were stim-
ulated with 1,000 U IFN-, TNF- (10 ng/l), or IL-2 (83 ng/l) (28) for
24 h, whereupon cells were washed and resuspended in cell lysis buffer
from an RNA extraction kit (RNeasy kit; Qiagen, Hilden, Germany). For
all stimulations, RNA was extracted, and gene expression was assessed for
TRIM5 and TRIM22. Cells were also lysed with CytoBustor protein
extraction reagent (catalog no. 71009-3; Novagen, Merck, Darmstadt,
Germany) supplemented with a protease inhibitor cocktail (catalog no.
P8340; Sigma) for Western blotting of TRIM5 and TRIM22. All experi-
ments were performed in triplicate.
Short interfering RNA transfection and pseudotyped HIV-1 infec-
tion. Three unique 27-mer short interfering RNA (siRNA) duplexes for
human TRIM5 (TRIM5.1 [catalog no. SR31385A], TRIM5.2 [catalog
no. SR31385B], TRIM5.3 [catalog no. SR31385C], and TRIM5.4 [a mix-
ture of the 3 TRIM5 siRNAs]), three for TRIM22 (TRIM22.1 [catalog
no. SR307012A], TRIM22.2 [catalog no. SR307012B], TRIM22.3 [catalog
no. SR307012C], and TRIM22.4 [a mixture of the 3 TRIM22 siRNAs]),
and a universal scrambled negative-control siRNA (catalog no. SR30004)
were chemically synthesized by Origene (Origene Technologies, New
York, NY).
Six million CD4 cells or neuroblasts were transduced with 20 M
TRIM5- and TRIM22-specific siRNA or control siRNA by using the
Bio-Rad Gene Pulser II apparatus (Bio-Rad, Berkeley, CA) at 100 V and
1.9 mA.
Forty-eight hours after transfection, cells were stimulated with or
without 6,000 U IFN- in a 24-well plate (6  106 cells/well) for 24 h. All
experiments were performed in triplicate. Cells were harvested for
TRIM5 and TRIM22 gene expression analysis and Western blotting.
Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped HIV-1
virions of HIV laboratory-derived strain JCRSF were generated in HEK
293T cells by using JCRSF and VSV-G plasmids, respectively (generously
provided by Warner Greene, UCSF), as described previously (29, 30).
CD4 T cells and neuroblasts were infected with a VSV-G-pseudotyped
HIV-1 laboratory strain (JRCSF) by spinoculation (31). In brief, the virus
was coincubated with 6  106 cells in each well of a 24-well plate and
centrifuged for 90 min at 1,500 rpm at 21°C. Cells were washed twice and
incubated for a further 48 h at 37°C in 5% CO2. The mean infection rate
(based on intracellular detection of p24 by flow cytometry) was 48%
(range, 15.4 to 74%) by 48 h after infection.
Cells transfected with the above-mentioned siRNAs were infected
with a VSV-G-pseudotyped HIV-1 laboratory strain (JRCSF) (600 ng of
p24/ml), as described above, and incubated for 48 h. Cell lysates were
harvested and analyzed by using a p24 Vironostika HIV-1 Antigen Micro-
elisa kit (bioMérieux, Durham, NC).
RNA isolation and analysis. For all PBMCs and CNS-derived patient
samples, RNA was extracted immediately after thawing, and counting of
cells was performed without in vitro stimulation. RNA was extracted from
2  106 PBMCs and all available CSF cells by using the RNeasy kit (Qia-
gen) according to the manufacturer’s instructions. RNA integrity was
confirmed by using morpholinepropanesulfonic acid (MOPS) gels. The
total RNA concentration was quantified, and samples were used only if the
optical density at 260 nm (OD260)/OD280 ratio was 1.90 or higher. All
RNA samples were DNase treated. One microgram of total RNA from
each sample was reverse transcribed by using the iScript cDNA synthesis
kit (Bio-Rad). For the CSF samples, all RNA extracted was reversed tran-
scribed.
RNA quantitation by real-time PCR. The PCR primers and cycling
conditions used for MxA (to represent a universal IFN-I readout [32]),
TRIM5, and TRIM22 real-time quantitative PCR were validated in our
laboratory and are shown in Table 1. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was validated as the most suitable reference gene
among 5 genes based on PCR efficiency. Each PCR mixture was com-
prised of 0.5 pmol/l (for MxA, TRIM5, and TRIM22) or 0.25 pmol/l
(for GAPDH) of each primer, 5 l SYBR green I master mix (2)
(Roche), 1 g cDNA, and water to 10 l. Reactions were run in duplicate
on a Roche LightCycler 480 version 1.5 instrument, with 1 cycle at 95°C
(10 min) followed by 45 cycles consisting of denaturation, annealing, and
extension steps (Table 1). Detection of the fluorescent products was car-
ried out at the end of the 72°C extension period. To confirm amplification
specificity, the PCR products were subjected to a melting-curve analysis
and agarose gel electrophoresis. Serial dilutions of cDNA from total RNA
were performed for each target gene. These dilutions served as standard
curves for quantitative analysis.
Western blotting. Briefly, cell lysates were mixed with 4 Laemmli
sample buffer (catalog no. 161-0747; Bio-Rad) and boiled for 10 min.
Samples were loaded onto 4 to 15% PAGE gels (catalog no. 456-1083;
Bio-Rad) and electrophoresed for 90 min at 80 V in SDS running buffer.
Separated proteins were transferred onto nitrocellulose (catalog no. 170-
4270; Bio-Rad) for 30 min by using the Trans-Blot Turbo transfer system
(catalog no. 170-4155; Bio-Rad). The nitrocellulose membrane was then
washed three times in Tris-buffered saline with Tween 20 (TBST) (catalog
no. 170-6435; Bio-Rad) for 10 min. The nitrocellulose membrane was
blocked with 5% bovine serum albumin (BSA) (catalog no. 10735094001;
Roche) in TBST. The membrane was then incubated with the primary
antibody (TRIM5, TRIM22, or tubulin) in 5% BSA (catalog no.
10735094001; Roche) in TBST at a 1:125, 1:500, or 1:5,000 dilution over-
night, followed by three washes in TBST for 10 min. Antibodies used in
this Western blot analysis were goat polyclonal anti-TRIM5 (catalog
no. ab4389; Abcam), rabbit polyclonal anti-TRIM22 (catalog no.
HPA003575; Sigma Prestige), and mouse polyclonal anti-alpha-tubulin
(catalog no. ab7291; Abcam). The membrane was incubated with the
secondary antibody (anti-goat, anti-rabbit, or anti-mouse) at a 1:20,000
TABLE 1 Primers used in this study
Gene
GenBank
accession no. Sequence (5=–3=)a
Cycling conditions (denaturation, annealing, and
extension steps)
MxA NM_0024462 5=-AAGCTGATCCGCCTCCACTT-3= (F) 95°C for 15 s, 60°C for 15 s, and 72°C for 15 s
5=-TGCAATGCACCCCTGTATACC-3= (R)
TRIM5 NM_033034 5=-AGGAGTTAAATGTAGTGCT-3= (F) 95°C for 15 s, 60°C for 15 s, and 72°C for 15 s
5=-ATAGATGAGAAATCCATGGT-3= (R)
TRIM22 NM_006074 5=-GGTTGAGGGGATCGTCAGTA-3= (F) 95°C for 15 s, 60°C for 15 s, and 72°C for 15 s
5=-TTGGAAACAGATTTTGGCTTC-3= (R)
GAPDH NM_002046 5=-AAGGTCGGAGTCAACGGATT-3= (F) 95°C for 15 s, 65°C for 15 s, and 72°C for 15 s
5=-CTCCTGGAAGATGGTGATGG-3= (R)
a F, forward; R, reverse.
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dilution in 5% BSA in TBST for 1 h on a rocker, followed by three washes
in TBST for 10 min. Antibody-antigen complexes were detected by using
enhanced chemiluminescence reagents (SuperSignal West Dura extend-
ed-duration substrate, catalog no. 00034075; Thermo Scientific, Pierce
Protein Research, Rockford, IL, USA). Proteins were visualized by using
the ChemiDoc XRS system with Image Lab software (catalog no. 170-
8265; Bio-Rad).
Statistical analysis. All expression data were log transformed to en-
sure normality. Values are expressed as medians. Differences between
matched PBMC and CSF samples were evaluated by using Student’s t test
for paired data. Differences between cohorts were compared by using
analysis of variance (ANOVA) or a Kruskal-Wallis test with Tukey’s or
Dunn’s multiple-comparison test, respectively. We correlated TRIM5
and TRIM22 to IFN-I gene expression values and all gene expression
values to viral load and CD4 T cell counts using Pearson’s correlation.
Scatter plots and bar graphs were generated by using Instat Graphpad
Prism V.5. All statistical analyses were performed by using Instat Graph-
pad Prism V.5 and SAS version 9.3 (SAS Institute, Inc., Cary, NC). P
values of 0.05 were considered statistically significant.
RESULTS
Cohort characteristics. The samples analyzed consisted of 19
HIV-1-uninfected participants, 28 HIV-1-infected participants
with primary infection, and 26 chronically infected participants.
The mean ages were 35 years (range, 19 to 54 years), 29 years
(range, 18 to 59 years), and 33 years (range, 12 to 42 years), re-
spectively, and percentages of females were 100% (19 partici-
pants), 100% (28 participants), and 73.1% (19 participants), re-
spectively. Although the cohorts differed significantly in terms of
gender (P  0.01), gene expression values did not differ signifi-
cantly between males and females in the chronic cohort (data not
shown).
Expression of IFN-I (MxA), TRIM5, and TRIM22 in com-
partments and according to HIV-1 infection status or phase.
Here, we sought to better understand the relationship between the
expression of TRIM5, TRIM22, and a widely utilized universal
correlate of IFN-I induction, myxovirus resistance protein A
(MxA), in primary (or early) versus chronic HIV-1 infection. Fur-
thermore, it is unknown whether TRIM E3 ligases are expressed in
cells that reside or home to the CNS, a remote anatomical site that
may represent a significant reservoir of HIV replication and where
adaptive immune responses may be limited. mRNA expression
levels were measured in PBMCs from 19 HIV-1-negative individ-
uals and 28 HIV-1-infected samples from patients with primary
infection. In addition, expression levels were measured in 26
matched CSF and PBMC samples obtained during the chronic
phase of HIV-1 infection. Patients with chronic infection had sig-
nificantly higher levels of MxA (P  0.0001) and TRIM22 (P 
0.0052) (Fig. 1A and C) than did subjects in the HIV-1-negative
group. Similarly, patients with primary infection also had higher
levels of MxA (P  0.05) and TRIM22 (P  0.0171) than did
subjects in the HIV-1-negative group (Fig. 1A and C). Both the
primary and chronically infected patients had lower levels of
TRIM5 (P  0.0001) than did the HIV-1-negative group (Fig.
1B). We analyzed mRNA levels of MxA, TRIM5, and TRIM22 in
both PBMCs and CSF-derived cells. We found that there were
higher levels of MxA (P  0.0022) and TRIM5 (P  0.0001) in
CSF cells than in PBMCs (Fig. 1D and E); however, there was no
significant difference in TRIM22 levels (Fig. 1F).
Although both TRIM5 and TRIM22 are interferon response
genes in vitro, we previously found no correlation between
TRIM5 and IFN-I in the primary HIV-1 infection phase, in con-
trast to TRIM22 levels, which strongly correlated with IFN-I (17).
We therefore next explored the relationships between TRIM5,
TRIM22, and IFN-I (MxA) expression in the periphery and the
CNS compartment during chronic HIV-1 infection. There was no
correlation between TRIM5 and MxA in CSF cells or PBMCs
(Fig. 1G). We found a significant positive correlation between
TRIM22 and MxA in CSF cells (r  0.75; P  0.0001) and PBMCs
(r  0.39; P  0.04) (Fig. 1H). In addition, there was a significant
positive correlation between TRIM22 and TRIM5 in PBMCs
(r  0.475; P  0.014) (Fig. 1I). Taken together, these data suggest
that there is a greater correlation between IFN-I and TRIM22
expression in vivo, whereas TRIM5 expression dynamics are
more unique and seemingly independent of IFN-I in different
phases or compartments of HIV-1 infection.
Cell populations in matched CSF samples and PBMCs and
baseline expression of TRIM5 and TRIM22 in immune cells.
Differential TRIM E3 ligases and MxA expression in the blood
versus CSF-derived cells raised the possibility that this may be
determined by distinct immune cells or proportions that reside in
these separate compartments. We therefore next investigated the
type of immune cells that could be detected in matched PBMCs
versus CSF samples from participants with chronic HIV-1 infec-
tion. Figure 2A shows representative flow cytometry plots with the
gating strategy employed to define different cell populations.
We found that the CNS compartment had significantly higher
proportions of T cells (P  0.0134) and natural killer (NK) cells
(P  0.0008) (Fig. 2B) than did matched PBMCs. Lower numbers
of monocytes were noted in CSF than in PBMCs (P  0.0001)
(Fig. 2B). These differences in specific cell subsets between the
PBMC and CNS compartments led us to investigate mRNA levels
of TRIM5 and TRIM22 in monocytes, CD4 T cells, and NK
cells isolated from HIV-1-negative participants. Higher levels of
TRIM5 were noted in CD4 T cells (P  0.0001) and NK cells
(P  0.0001) than in monocytes (Fig. 2C). No significant differ-
ences in TRIM22 expression in these cell populations was noted
(Fig. 2D). These data suggest that, at least during CNS inflamma-
tion, immune cells, particularly T cells, can traffic to and accumu-
late in this compartment compared to the periphery. Accumula-
tion of CD4 T cells in this compartment probably contributed to
the higher level of TRIM5 expression observed in CSF cells.
Association of antiviral gene expression with markers of dis-
ease progression in primary and chronic HIV-1 infection. As
expected, patients with primary HIV-1 infection had significantly
higher CD4 T cell counts and lower plasma viral loads than did
patients chronically infected with HIV (P  0.0001 for both) (Fig.
3A and B). There were no significant differences in viral load be-
tween plasma and CSF in the chronically infected group (Fig. 3C).
To determine if MxA, TRIM5, or TRIM22 gene expression
was associated with viral control during chronic infection, we in-
vestigated the correlation between viral loads and gene expression
levels. No significant correlation for MxA or TRIM5 and viral
load was noted for both the periphery and the CNS (Fig. 3D and
E). However, there was a negative correlation between TRIM22
mRNA levels in PBMCs and plasma viral load (r  	0.397; P 
0.04) (Fig. 3F). These data are consistent with our previous find-
ings for acute HIV-1 infection in which TRIM22 but not TRIM5
levels showed a weak negative correlation with plasma viral load
(17).
Regulation of TRIM5 and TRIM22 by IFN- and proin-
flammatory cytokines TNF- and IL-2. Our findings of differen-
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tial expression kinetics in vivo between TRIM5 and TRIM22 and
the lack of association between TRIM5 and MxA expression lev-
els suggested that there may be subtle differences in the transcrip-
tional regulation of these proteins besides IFN-I. We hypothesized
that proinflammatory cytokines may play a role in the regulation
of TRIM E3 ligases. To better understand how TRIM5 and
TRIM22 are regulated in immune cells targeted by HIV-1, CD4
lymphocytes and monocytes purified by negative selection were
stimulated with IFN-, TNF-, or IL-2, and expression of the
TRIM E3 ligases was assessed by reverse transcription real-time
PCR and Western blotting (Fig. 4A to E). IFN- significantly but
differentially induced TRIM5 mRNA expression in CD4 cells
and monocytes (P  0.05 for both), with higher levels of upregu-
lation noted for the former (Fig. 4A). Likewise, TRIM22 mRNA
levels increased significantly (P  0.05) in both CD4 lymphocytes
and monocytes in response to IFN-I stimulation, with higher lev-
els of induction noted for CD4 cells (Fig. 4B). A modest upregu-
lation of TRIM5 and TRIM22 mRNA levels in monocytes fol-
lowing IL-2 stimulation was noted. Next, we assessed whether
stimulation with IFN-, TNF-, or IL-2 modulated TRIM5 and
TRIM22 protein levels (Fig. 4C). CD4 cells stimulated with IFN-
expressed higher protein levels of TRIM5 than did unstimulated
cells (P  0.03), and there was no TRIM5 protein induction
noted following stimulation with either TNF- or IL-2 (Fig. 4C
FIG 1 Expression of antiviral factors according to HIV-1 infection status and compartment. (A to C) Expression of the IFN-I-responsive gene (MxA) (A),
TRIM5 (B), and TRIM22 (C) in PBMCs from HIV-1-uninfected versus -infected subjects. (D to F) Expression of MxA (D), TRIM5 (E), and TRIM22 (F) in
PBMCs versus CSF-derived cells from chronically infected patients. The samples from participants with primary infection were all collected within 12 months of
infection. One time point, closest to 12 months postinfection, was used per participant (n  28). For HIV-1-negative participants, only those who remained
HIV-1 negative during the entire follow-up period (2 years) were included in this analysis (n  19). The chronically infected group consisted of participants
presenting with chronic meningitis (n  26). Matched CSF samples and PBMCs from the same patients were analyzed (n  26). Data are depicted as normalized
ratios of MxA, TRIM5, or TRIM22 to GAPDH. Median expression levels between HIV-negative and HIV-positive samples were compared. (G to I) Correlations
(Pearson) between MxA and TRIM5 (G), TRIM22 and MxA (H), and TRIM22 and TRIM5 (I) in both CSF samples and PBMCs from patients with chronic
HIV-1 infection.
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and D). Monocytes stimulated with IFN- showed no significant
increase in TRIM5 protein levels compared to unstimulated cells
(Fig. 4C and D). CD4 cells and monocytes stimulated with IFN-
had higher protein levels of TRIM22 than did unstimulated cells
(P  0.03 and P  0.003, respectively). CD4 T cells also showed
increased TRIM22 protein expression levels following TNF-
stimulation (Fig. 4E).
We further tested whether IFN-, IL-2, or TNF- could mod-
ulate TRIM5 and TRIM22 in astrocytes and neuroblasts, cell
lines similar to HIV target cells in the CNS compartment. IFN-
significantly but differentially induced TRIM5 and TRIM22
mRNA and protein levels in astrocytes and neuroblasts (P  0.05
for all), whereas neither IL-2 nor TNF- had a significant effect on
TRIM E3 ligases expression (data not shown).
These data show that although both TRIM5 and TRIM22 are
generally IFN- inducible in most cells, some subtle differences
may also exist between diverse immune cells, and some immuno-
regulatory cytokines may also play a role in the regulation of
TRIM E3 ligases.
siRNA-mediated silencing of TRIM5 or TRIM22 in CD4
cells enhances HIV-1 infection. To further explore the impact of
TRIM5 and TRIM22 on HIV-1 infection in primary immune cells
targeted by HIV-1, we performed transient knockdown of these genes
in CD4 lymphocytes, which were previously demonstrated to up-
regulate the expression of the TRIM E3 ligases in response to IFN-
(15, 17). Gene knockdown by 3 different siRNAs, each corresponding
to TRIM5 and TRIM22 coding sequences, significantly reduced
mRNA and protein levels of both genes in the presence of IFN-, as
verified by RT-PCR and Western blotting (Fig. 5A to F). Under
IFN- stimulation, CD4 cells treated with TRIM5.1, TRIM5.2,
TRIM5.3, and TRIM5.4 (a mixture of the four TRIM5 siRNAs)
showed a 28 to 64% reduction in mRNA levels and a 15 to 61%
reduction in protein levels compared to control treated cells (Fig. 5A,
C, and E). TRIM22 knockdown with the siRNA TRIM22.1,
TRIM22.3, or TRIM22.4 (a mixture of the 3 TRIM22 siRNAs) re-
sulted in a 44 to 54% reduction in mRNA levels and a 47 to 91%
reduction in protein levels (Fig. 5B, D, and F), while TRIM22.2 siRNA
knockdown data were inconsistent (data not shown).
FIG 2 TRIM5 and TRIM22 expression in different immune cells. (A) Representative flow cytometry plots showing the gating strategy employed to define
different cell populations. (Top) Cells were first gated for singlets (forward scatter height [FSC-H] versus forward scatter area [FSC-A]), and CD4 T cells were
defined from the lymphocyte gate (side scatter area [SSC-A] versus FSC-A) as CD3 CD4 events. (Middle) Flow cytometry plots illustrate the gating for B cells
as CD3	 CD19 cells and monocytes as CD3	 CD19	 CD56	 CD14 cells. (Bottom) NK cells were defined as CD3	 CD56 CD16 cells. (B) Data were
compared between each subset of cells in the CSF and PBMCs only by using the paired t test. Magnetic cell sorting was employed to isolate CD4 cells and
monocytes from 6 fresh HIV-1-negative PBMC samples. Natural killer cells were isolated by using the Easy Sep negative-selection human NK cell enrichment kit
(Stemcell Technologies). (C and D) Different cell populations were analyzed for TRIM5 (C) and TRIM22 (D) mRNA expression. Data are depicted as
normalized ratios of TRIM5 or TRIM22 to GAPDH.
Singh et al.
4296 jvi.asm.org Journal of Virology
Next, we assessed the impact of TRIM5 and TRIM22 knock-
down on HIV-1 infection in CD4 cells. Following IFN- stimula-
tion and infection with VSV-G-pseudotyped HIV-1, TRIM5 or
TRIM22 knockdown cells showed higher levels (at least 1.3-fold
and 1.7-fold higher, respectively) of intracellular p24 antigen than
did control cells (P  0.0001) (Fig. 5G and H).
siRNA-mediated silencing of TRIM5 or TRIM22 in neuro-
blasts enhances HIV-1 infection. HIV-1 is known to productively
replicate in macrophages and microglia of the CNS, but it also
infects astrocytes and other CNS cells via a CD4-independent
pathway (33–35). To explore the possible differential antiviral role
of TRIM E3 ligases in CNS-derived cells compared to CD4 lym-
phocytes, we performed transient knockdown of TRIM5 and
TRIM22 and assessed the impact on IFN--induced anti-HIV-1
activity in neuroblasts (ATCC CRL-2137). Cell lines were used in
lieu of patient-derived primary neuronal cells. Significantly lower
levels of TRIM5 and TRIM22 mRNA and protein levels were
noted in the knockdown cell lines than in the control cells trans-
fected with nontargeting siRNA (all P  0.01), (Fig. 6A to D). It
should be noted that knockdown of the TRIM E3 ligases appeared
to be more efficient in the neuronal cell line than in primary CD4
cells, possibly because this cell line is more homogenous and easier
to transfect. Furthermore, differences in expression were more
pronounced with IFN- stimulation than without. Upon infec-
tion with VSV-pseudotyped HIV, both the TRIM5 and TRIM22
knockdown cell lines showed higher (1.3- and 2.3-fold increases,
respectively) intracellular p24 antigen levels than those of the con-
trol (scrambled siRNA-treated) cell line after IFN- stimulation
(P  0.0001 and P  0.001, respectively) (Fig. 6E and F). These
data confirm the overall inhibitory effect of these TRIM E3 ligases
on diverse cells despite subtle differences in the level or efficiency
of the viral blockade.
DISCUSSION
TRIM E3 ligases represent an important component of the innate
immune response against retroviral infections (36). However,
TRIM E3 ligases are a heterogeneous group of proteins, and little is
known about the contribution of specific members of this family
to antiviral activity in vivo and the factors that may contribute to
differential expression or effectiveness in blocking viral replica-
tion (15, 36, 37). We hypothesized that TRIM E3 ligases, as a
component of the innate immune system, may play a significant
role in blocking retroviral infection during the early phases of
infection and in a remote anatomical site likely deficient in a ro-
bust adaptive immune system. We demonstrate here that
TRIM5 and TRIM22 are differentially regulated according to
infection status or phase of infection. We also show that TRIM5
and TRIM22 have different or compartmentalized kinetics of ex-
pression and show some compartment-specific heterogeneity in
association with HIV-1 viral load, a marker of viral replication.
Furthermore, we show that while both TRIM5 and TRIM22
mRNA and protein expressions are strongly induced in CD4 T
cells, monocytes, and neuronal cell lines by IFN-, there are some
cell-specific differences, with apparently stronger induction in
CD4 T cells, and additionally, cytokines such as IL-2 and TNF-
FIG 3 Association of antiviral gene expression with markers of disease progression in primary and chronic HIV-1 infection. (A and B) Differences between
samples from participants with primary infection closest to 12 months postinfection (n  28) and samples from chronically infected patients (n  28) were
compared in terms of CD4 T cell counts and viral loads. (C) Viral loads in plasma and CSF samples from the chronically infected group were compared. (D to
F) Pearson correlations were performed for MxA (D), TRIM5 (E), and TRIM22 (F) expression levels and viral loads in the CSF or peripheral blood compart-
ments in the chronically HIV-1-infected group.
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may also subtly and differentially impact the expression of these
antiviral proteins.
The majority of studies of host restriction factors in antiviral
immunity have been performed in vitro, devoid of the complexity
that the pathogen encounters in vivo in the form of different arms
of the immune system and viral replication cofactors that all co-
exist and contribute to disease outcome. Here, we characterized
the in vivo expression patterns of two TRIM E3 ligases, TRIM5 and
TRIM22, in PBMCs. Both proteins were previously shown to be
type I interferon inducible (15, 38, 39), and considering that
TRIM22 is located downstream of the TRIM5 gene (40, 41), we
anticipated similar expression patterns. However, our data show
subtle differences in the expression of these TRIM E3 ligases at the
transcriptional level, with TRIM22 more closely mimicking the
expression of the IFN-I surrogate MxA in uninfected subjects as
well as in early and chronic HIV-1 infection phases than TRIM5
(Fig. 1A to C). Likewise, in comparing MxA, TRIM5, and
TRIM22 expression levels in PBMC versus CNS compartments,
MxA and TRIM22 had similar (but not identical) expression pat-
terns, whereas there were marked differences in the expression
levels of TRIM5 between the two compartments. Our findings of
higher levels of MxA in the CNS compartment than in the periph-
ery are consistent with observations of IFN-I reported by other
groups (42–44). There was a significant positive correlation be-
tween MxA and TRIM22 but not between MxA and TRIM5
mRNA levels, even though TRIM22 and TRIM5 expression lev-
els correlated positively. These data are consistent with a model
where, in vivo, there is tighter regulation of TRIM22 than of
TRIM5 by type I interferon but also offer the suggestion that
other independent regulatory mechanisms are involved. Further
studies will be needed to elucidate these non-type I interferon
mechanisms of TRIM E3 ligase regulation in HIV-uninfected in-
dividuals but also in the context of HIV infection and in different
phases and compartments of viral infection.
In this study, we found that MxA and TRIM22 levels were
significantly elevated during chronic HIV-1 infection and in CNS-
derived cells compared to PBMCs. Levels of type I interferons are
known to be elevated due to generalized immune activation,
which in turn has been associated with accelerated HIV/AIDS pro-
gression (45, 46). Therefore, elevated levels of MxA and TRIM22
in this context may reflect generalized immune activation as op-
posed to a robust antiviral immune response. Interestingly,
TRIM5 levels were low in chronic HIV-1 infection but were el-
evated in the CNS compartment compared to the periphery,
FIG 4 Regulation of TRIM5 and TRIM22 by IFN- and select proinflammatory cytokines in immune cells. Shown is the effect of IFN- stimulation and
proinflammatory cytokine stimulation of CD4 cells and monocytes on antiviral gene expression. Cells from healthy donors were stimulated for 24 h. (A and B)
Total cellular RNA from cells was then subjected to real-time RT-PCR to measure mRNA levels using primers specific for TRIM5 (A) and TRIM22 (B) and
GAPDH. (C to E) Protein expression analyses of TRIM5 (C and D) and TRIM22 (C and E) are shown. Results shown in panels A, B, D, and E are the means of
three independent experiments (with bars indicating ranges), each performed in duplicate.
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FIG 5 siRNA-mediated silencing of TRIM5 or TRIM22 in CD4 cells. To determine the functional impact of TRIM5 and TRIM22 on HIV-1 replication in
CD4 cells, gene knockdown experiments were performed by transducing the cells with siRNA against TRIM5 or TRIM22 or a nontargeting (scramble) control
siRNA, with or without IFN- stimulation for 24 h. (A to F) Knockdown of TRIM5 or TRIM22 by siRNA in the absence or presence of IFN- was validated by
mRNA RT-PCR (A and B) and Western blotting (C to F). Cells were then challenged with a VSV-G-pseudotyped HIV-1 laboratory strain (JRCSF) (600 ng of
p24/ml) for 48 h. (G and H) Culture lysates were collected and assessed for HIV p24 antigen levels by an enzyme-linked immunosorbent assay. Data are depicted
as fold changes, where the levels of p24 antigen in knockdown cells were divided by the levels in control cells. TRIM22.2 siRNA knockdown efficiency was
inconsistent, and the data are thus excluded from the graphs.
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which is probably attributable to an accumulation of activated
CD4 T cells in the CNS in our study cohort. TRIM5 has been
reported to positively modulate innate immune responses and has
been demonstrated to be a pattern recognition receptor (47, 48).
Our data also revealed distinct compartmentalization of immune
cells between the CNS and periphery, with enrichment of NK and
T cells in the CNS compartment compared to matched samples
from the periphery. These findings are consistent with other phe-
notypic characterizations of CNS samples from patients with
meningitis (49–51); however, further work is needed to address
whether this distinct sublocalization has an impact on disease
pathogenesis in these locations.
We also investigated the association of antiviral gene expres-
sion and viral load, a commonly used marker of disease progres-
FIG 6 siRNA-mediated silencing of TRIM5 or TRIM22 in neuroblasts. To determine the functional impacts of TRIM5 and TRIM22 on HIV-1 infection in
neuroblasts, gene knockdown experiments were performed by transducing the cells with siRNA against TRIM5 or TRIM22 or a nontargeting (scrambled)
control siRNA, with or without IFN- stimulation for 24 h. (A to D) Knockdown of TRIM5 or TRIM22 by siRNA in the absence or presence of IFN- was
validated by mRNA RT-PCR (A and B) and Western blotting (C and D). Cells were then challenged with a VSV-G-pseudotyped HIV-1 laboratory strain (JRCSF)
(600 ng of p24/ml) for 48 h. (E and F) Culture lysates were collected and assessed for HIV p24 antigen levels by an enzyme-linked immunosorbent assay. Data
are depicted as fold changes, where levels of p24 antigen in knockdown cells were divided by levels in control cells.
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sion, extending our previous work performed exclusively with re-
cently infected individuals (25). In agreement with previous
studies, there was no correlation between viral loads and TRIM5
expression in patients with either primary or chronic HIV-1 in-
fection. Interestingly, TRIM22 expression in PBMCs from pa-
tients with chronic HIV-1 infection showed a moderate negative
correlation with viral loads. We have previously shown that
TRIM22 has a negative correlation with plasma viral load and a
positive correlation with CD4 T cell counts in primary HIV-1
infection (17). Collectively, the in vitro and in vivo data provide
strong evidence of immune pressure by TRIM22 against HIV-1.
In this study, we also sought to better understand how TRIM
E3 ligases are regulated in CD4 cells and monocytes, primary
HIV-1 target cells which were also found in high proportions in
the CNS samples analyzed in this study. We also explored the
expression patterns and antiviral activities of TRIM5 and
TRIM22 in neuronal cell lines in an attempt to begin to unravel
the role of intrinsic immunity in CNS-derived cells. Specifically,
we investigated how IFN- and select proinflammatory cytokines
affect the expression of TRIM5 and TRIM22 in primary and
immortalized neuronal cells. We found that TRIM5 and
TRIM22 were IFN inducible in CD4 cells, monocytes, and neuro-
nal cell lines. Most previous studies on immune regulation of
TRIM E3 ligases have focused on IFN-, but we reasoned that due
to the discordance in the relationship between IFN-I and TRIM5
versus IFN-I and TRIM22 that we sometimes found in vivo, other
regulatory cytokines may be involved.
We found that the pattern of expression of TRIM5 and
TRIM22 was cell dependent, with higher IFN- induction of
TRIM E3 ligases in CD4 lymphocytes than in monocytes. Proin-
flammatory cytokines generally had a modest impact on TRIM E3
ligase expression, with TNF- induction of TRIM22 in CD4 cells
being the most notable effect. Yu and colleagues previously
showed that TRIM22 overexpression could significantly induce
the secretion of proinflammatory cytokines in the human macro-
phage cell line U937 in an NF-
B-dependent manner (52). These
data suggest that some proinflammatory cytokines can induce
TRIM E3 ligase production in some cells. One of the main features
of advanced HIV-1 infection and associated chronic immune ac-
tivation is the dysregulation of cytokine production, including
elevated TNF- levels (53, 54). This proinflammatory cytokine
dysregulation may also have contributed to elevated TRIM E3
ligase expression levels in chronic HIV infection and in the CNS.
Collectively, these data suggest that while IFN- appears to be
primarily responsible for the induction of TRIM E3 ligases, subtle
cell-specific differences exist, and proinflammatory cytokines may
also play a minor role in the regulation of these proteins in pri-
mary cells.
Finally, in this study, we investigated whether human TRIM5
or TRIM22 has any functional effects on HIV-1 infection in CD4
cells and neuroblasts. Knockdown of either TRIM5 or TRIM22
in either cell type revealed that both proteins had antiviral activity.
These findings are consistent with previous studies suggesting that
human TRIM5 and TRIM22 have some anti-HIV-1 activity, es-
pecially in saturating doses (13, 15, 17, 47). Clearly, the level of
antiviral activity of human TRIM5 does not match that of its
rhesus counterpart, and therefore, unsurprisingly, there was no
correlation between human TRIM5 levels and viral load in any
compartment. Based on these findings, we speculate that targeted
enhancement of the expression of TRIM22 in HIV-1-infected in-
dividuals may be beneficial in reducing viral load and could be
employed as a novel antiviral strategy. Whether one can achieve
targeted enhancement of a host restriction factor without induc-
ing pathological generalized immune activation will require fur-
ther studies, but our data are suggestive that under certain circum-
stances, TRIM E3 ligases, and in particular TRIM22, have antiviral
effects.
Some limitations of the current study should be noted. First,
due to sample limitation and to allow comparison of in vivo data,
we assessed the expression of the antiviral factors here at the tran-
scriptional level only. Future studies should aim at analyzing pro-
tein expression levels of these factors in patient samples. Second,
we used bulk PBMCs or CSF-derived cells rather than specific
subsets, although the latter limitation was then partially addressed
by performing in vitro experiments using sorted subsets and/or
cell lines. Clearly, more studies using well-characterized human
samples are needed to better understand the role of intrinsic im-
munity in HIV control and to assess whether there is a plausible
pathway to harness these factors for immunotherapeutic or other
novel antiviral approaches. It is also worth noting that TRIM E3
ligase knockdown using siRNA showed variable efficiency, with
apparently high antiviral factor expression levels under IFN-
stimulation in some cases. However, even under these circum-
stances, it was clear that the knockdown of either factor limited
VSV-G-pseudotyped HIV infection of target cells.
In conclusion, in this study, we have characterized the expres-
sion of the interferon-responsive gene MxA and the TRIM E3
ligases TRIM5 and TRIM22 in peripheral blood mononuclear
cells from HIV-1-uninfected individuals and from patients during
the early or chronic phase of HIV-1 infection. We demonstrate
that in vivo, there may be some subtle differences in the expres-
sions of TRIM5 and TRIM22, despite the two being IFN-I-in-
ducible genes in vitro. Furthermore, differences in expression pro-
files between the PBMC and CNS compartments were also noted,
which are likely due to differences in cellular composition between
the compartments. TRIM22 but not TRIM5 expression levels
correlated negatively with HIV-1 viral loads, suggesting that
TRIM22 may be exerting significant antiviral activity in vivo. We
have demonstrated that in addition to type I interferons, some
immunoregulatory cytokines may modestly regulate the expres-
sion of TRIM5 and TRIM22 in different HIV-1-susceptible im-
mune cells; however, the impact of these factors is cell type spe-
cific. Our study provides evidence for the role of TRIM E3 ligases
in intrinsic antiviral immunity in peripheral blood and in a remote
anatomical site of infection. These data have implications for a
better understanding of HIV pathogenesis and provide a basis for
further work to explore the contribution of host restriction factors
to immunopathogenesis and novel therapeutic targets.
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